Modality
ADC
MOA
HER2
Target
C5
Pathway
JAK/STAT
T2D
Development Pipeline
Preclinical
~Jun 2016
→ ~Sep 2017
Phase 1
Dec 2017
→ Mar 2028
Phase 1Current
NCT03830956
57 pts·T2D
2020-01→2028-03·Not yet recruiting
NCT04584277
619 pts·T2D
2017-12→2026-02·Recruiting
676 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-02-072mo agoInterim· T2D
2028-03-051.9y awayInterim· T2D
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1
Recruit…
P1
Not yet…
Catalysts
Interim
2026-02-07 · 2mo ago
T2D
Interim
2028-03-05 · 1.9y away
T2D
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03830956 | Phase 1 | T2D | Not yet recr... | 57 | eGFR |
| NCT04584277 | Phase 1 | T2D | Recruiting | 619 | Mayo |
Competitors (10)